key disease areas
Circulating proteins are powerful indicators of cardiovascular disease. Explore >25 CVD publications featuring SomaScan data.
Identify and characterize cancers and predict response to immunotherapy by measuring circulating proteins.
NASH & NAFLD
The SomaScan Assay can be used to detect biomarkers associated with nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
Proteomics can shed light on the pathology of infectious disease, discover predictors of disease progression, or demonstrate treatment response.
2 ways to engage, 1 powerful platform
7,000 highly reproducible protein measurements from just 55 µl blood
Biomarker discovery and clinical insights from a single sample
18 clinically validated metrics derived from proteomic data on just 55 µl blood
For a more targeted approach, disease specific and custom panels are also now available
SAME GENOTYPE. DIFFERENT PHENOTYPE.
PROTEIN ASSAYS COMPLEMENT GENOMICS TO IDENTIFY:
- Patient subpopulations
- Novel therapeutic targets
- New disease applications for approved drugs
- Possible safety concerns
- Mechanisms of action
The SomaScan platform is optimized for clinical proteomics
The largest commercial proteomic assay on the market, providing over 7,000 protein measurements.
Our workflow is massively multiplexed with considerable controls to yield fast, accurate data.
With average CVs of ~5%, SomaScan reagents provide reproducible results for patient samples and healthy controls.
10 log dynamic range
Our unique approach detects very rare proteins and highly abundant proteins from the same sample simultaneously.
join our customers
Louisiana State University
Henry Ford Health System
Leeds Centre for Personalised Medicine and Health
liquid health check
Protein signatures from 17,000 samples were compared with traditional health indicators to generate 13 predictive models.
Circulating proteins were used to identify 27 network modules associated with CVD, metabolic diseases, and overall survival.